Cyxone brings forward interim report to August 17, 2018
Cyxone AB (publ) announced today that the company has decided to bring forward the publication of the interim report for the period January-June 2018.
Work on the interim financial report for the second quarter of 2018 has gone faster than expected, therefore, Cyxone will publish it on August 17, 2018, instead of August 29, 2018, as previously communicated.
Cyxone AB is a clinical stage biotech company with a portfolio of immunomodulating drugs for the treatment of autoimmune diseases such as multiple sclerosis (MS) and rheumatoid arthritis (RA). The company’s drug portfolio is based on two technological pillars in the form of oral molecules and cyclotide-based drugs that inhibit key processes in the body’s cells that are typically associated with various immune-related disorders. Cyxone’s technologies have the potential to address an unmet need and provide new effective and safe medicines that can improve the quality of life for patients affected by autoimmune diseases. The company has two drug candidates, T20K for MS in a preclinical program and Rabeximod for RA in clinical phase II-program. Cyxone’s Certified Adviser on the Nasdaq First North is Erik Penser Bank, +46 (0)8 4638000. www.cyxone.com